Larotinib/Larotinib correct storage conditions and expiry date instructions

Larotrectinib is an oral TRK (neurotrophic tyrosine kinase) inhibitor that is widely used to treat solid tumors with NTRK gene fusions. As a molecularly targeted drug, its storage conditions are directly related to the stability and efficacy of the drug. According to official information and recommendations from foreign drug regulatory agencies, larotrectinib should be stored at room temperature. The ideal storage temperature is between 20°C and 25°C. Short-term fluctuations in the range of 15°C to 30°C are allowed, but it should not be placed in extreme temperature environments, such as high temperature exposure or freezing. Avoiding contact with moisture, high humidity and strong light exposure is the key point in the storage and management of larotrectinib.

The two common dosage forms of larotrectinib are capsule preparations and oral solution preparations. Capsules are usually packaged in sealed plastic bottles, and the caps should be kept tightly closed to avoid the intrusion of air moisture. Oral solutions are more sensitive and need to be tightened immediately after use to avoid secondary contamination. It is recommended to store them in a cool place out of reach of children. In the unopened state, the solution preparation can be stored in the above temperature environment until the expiration date marked on the package. It is generally recommended to use the opened oral solution within 30 days to ensure stable drug activity.

The validity period of larotrectinib usually starts from the production date. The shelf life of capsule preparations is generally 24 months. The validity period of oral solutions may be slightly shorter, usually ranging from 12 to 18 months, because it contains liquid components and has poor stability. The expiry date should be clearly marked on the packaging and never use expired medicines. If there is color change, floc, sedimentation or other abnormalities in the medicine, stop using it immediately and consult a physician or pharmacist.

Patients should avoid mixing larotrectinib with other drugs during daily drug storage, especially avoid contact with volatile and corrosive chemicals, and should regularly check the status of the drugs. For cancer patients who need to use the drug for a long time, reasonable storage habits can not only extend the service life of the drug, but also help ensure the continuity and stability of treatment and avoid affecting the prognosis of treatment due to drug failure.

Reference materials:https://www.vitrakvi.com/